Volanesorsen for treating familial chylomicronaemia syndrome – guidance (HST13)

Volanesorsen is recommended for genetically confirmed familial chylomicronaemia syndrome in adults at high risk of pancreatitis when response to diet and triglyceride-lowering therapy has been inadequate.

Source:

National Institute for Health and Care Excellence